China-based biotech Transcenta Holdings Ltd (HKG: 6628) announced the appointment of Dr. Caroline Germa as its executive vice president of global drug development and chief medical officer (CMO). Dr. Germa will report directly to CEO Dr. Qian Xueming.
Role and Responsibilities
Dr. Germa will lead the global development and translational research teams, advancing the company’s molecule pipelines. She will conduct registrational trials to obtain approval from multiple global regulatory agencies, ensuring safety and compliance. Additionally, she will lead the company’s efforts with current and potential business partners to develop global clinical collaborations.
Professional Background
Prior to joining Transcenta, Dr. Germa held positions at Eli Lilly, Sanofi-Aventis, Novartis, Bristol-Myers Squibb (BMS), and AstraZeneca. She served as vice president and head of early clinical development at AstraZeneca Oncology and vice president of BMS oncology, leading a major oncology collaboration. At Novartis, she led the late-stage clinical development of several key oncology assets, including the global registration strategy and approval of CDK4/6 inhibitor Kisqali (ribociclib). While at Pfizer, she was the clinical director for anti-HER2 inhibitor Nerlynx (neratinib). Dr. Germa received her MD from the University of Paris and her medical oncologist degree from Lille University, along with a master’s degree in breast disease and immunology.-Fineline Info & Tech
